5 January 2019 - On the same day Celgene was announcing that it would be acquired by Bristol-Myers Squibb in the biggest pharma deal ever, the company was also raising the price of its blockbuster cancer drug.

The Summit, New Jersey-based biotechnology company, which has routinely increased the prices of its top-selling drugs, boosted the price of a 10 mg dose of Revlimid by 3.5% to $719.82 effective Jan. 3, according to price data compiled by Bloomberg Intelligence and First Databank. 

Cancer patients need many doses of Revlimid a year, and the overall cost can approach $200,000. The same dose cost $247.28 at the end of 2007.

Read Bloomberg article